<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247779</url>
  </required_header>
  <id_info>
    <org_study_id>ROBOGYN - 1004</org_study_id>
    <secondary_id>2010-A00605-34</secondary_id>
    <nct_id>NCT01247779</nct_id>
  </id_info>
  <brief_title>Perioperative Morbidity in Gyneco-oncology According to the Procedure : Coelioscopy Versus Robot-assisted Coelioscopy</brief_title>
  <acronym>ROBO-GYN</acronym>
  <official_title>Assessment of Perioperative Morbidity in Gyneco-oncology According to the Surgical Approach : Coelioscopy Versus Robot-assisted Coelioscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CRG : Groupe Francophone de Chirurgie Robotique en Gynécologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare perioperative morbidity of coelioscopy versus
      robot-assisted coelioscopy in cervical cancer, uterus cancer and ovarian cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Laparoscopic surgery, also called minimally invasive surgery (MIS), is a surgical method less
      invasive than classical laparoscopic open procedure. Particularly, MIS is used for resection
      of some gynecological cancer such as endometrial cancer, cervical cancer or ovarian cancer.
      Several studies demonstrated that MIS induce less surgical complications (bleeding,
      infections, post-operative pains...), shorter hospitalization time, earlier recovery of
      activity and better quality of life than laparoscopic open procedure.

      However, MIS is the selected method in only 9 to 25 % of gynecologic cancer surgery in
      France. This is likely due to the longer learning curve of MIS compared to laparoscopic open
      procedure.

      In 2001 the FDA allowed the use of robot assisted laparoscopic surgery (RALS). This technique
      adds some advantage to laparoscopic surgery. Indeed, surgeon operates with better precision
      while seated comfortably at a computer console viewing a 3-D image of the surgical field.
      Moreover learning curve of RALS is shorter than MIS. Comparative studies between RALS and MIS
      demonstrate an equivalence of these techniques for operation length and bleeding. However for
      surgery linked complications and time for recovery of activity, RALS had better results than
      MIS.

      Despite its expensive cost, RALS is now commonly used in North America (90% of prostatectomy
      and 40% of cancer linked hysterectomy). However RALS need to be evaluated in a randomized
      clinical trial before it's acceptation in gyneco-oncology in France.

      Thus, the purpose of the ROBOGYN clinical trial is to compare clinical benefit of RALS and
      MIS in a randomized study for patients with cancer of cervix, uterus or ovary.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2010</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perioperative morbidity at six months</measure>
    <time_frame>six months after surgery</time_frame>
    <description>To estimate the rate of complications within the first six months after surgery, according to the Clavien-Dindo and NCI CTCAE-v4.0 grading scales</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anesthesic and ventilator parameters</measure>
    <time_frame>every 30 min during the surgery</time_frame>
    <description>Description of anesthesic and ventilator parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative analgesia</measure>
    <time_frame>at 24h, 48h after sugery and until discharge</time_frame>
    <description>collect of antalgic treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgeon's ergonomy</measure>
    <time_frame>every hour during surgery (Borg scale), and at the end of intervention (NASA-TLX scale)</time_frame>
    <description>according to Borg and NASA-TLX scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>until 2 years after surgery</time_frame>
    <description>according to SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of surgical procedures</measure>
    <time_frame>during surgery</time_frame>
    <description>operative time (overall intervention, incision or &quot;skin-to-skin&quot;, robot).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>until 2 years after surgery</time_frame>
    <description>delay between the date of randomization and the date of the following event: local relapse, regional relapse, metastasis or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anatomopathology</measure>
    <time_frame>during surgery</time_frame>
    <description>rate of exeresis with histologically healthy resection margins (R0), number of lymph nodes removed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">386</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Uterus Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Standard Coelioscopy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>gynecologic surgery - standard coelioscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Robot-assisted coelioscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gynecologic surgery - robot assisted coelioscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>gynecologic surgery - standard coelioscopy</intervention_name>
    <description>lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy</description>
    <arm_group_label>Standard Coelioscopy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>gynecologic surgery - robot assisted coelioscopy</intervention_name>
    <description>lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy</description>
    <arm_group_label>Robot-assisted coelioscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with uterus cancer depending on hysterectomy ± pelvic lymphadenectomy or a
             restadification

          -  patient with cervical cancer depending on enlarged colpo-hysterectomy ± pelvic
             lymphadenectomy or a surgery after concomitant radiochemotherapy, or lombo aortic
             lymphadenectomy for a locally advanced cancer, or a restadification

          -  patient with cervical cancer depending on a restadification

          -  patient aged over 18 years

          -  previous antitumor treatment allowed but necessarily disrupted 20 days before
             inclusion

          -  WHO score equal or inferior to 3

          -  cirrhosis-related Child-Pugh score under or equal to A7 are allowed

          -  life expectancy equal or superior to 12 weeks

          -  patient affiliated to health insurance

          -  dated and signed informed consent

        Exclusion Criteria:

          -  metastatic disease

          -  pregnant or breastfeeding woman

          -  patient unable to proceed follow-up visit, because of geographic, social or mental
             reasons
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice NARDUCCI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret, Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric LAMBAUDIE, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Bordeaux, Hôpital Saint-André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille, Hôpital Jeanne de Flandres</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique KenVal</name>
      <address>
        <city>Nimes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Courlancy</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Roubaix</name>
      <address>
        <city>Roubaix</city>
        <zip>59056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest Site René Gauducheau</name>
      <address>
        <city>St HERBLAIN</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2010</study_first_submitted>
  <study_first_submitted_qc>November 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gynecology</keyword>
  <keyword>oncology</keyword>
  <keyword>coelioscopy</keyword>
  <keyword>robot</keyword>
  <keyword>morbidity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

